Molnupiravir, an oral prodrug of N-hydroxycytidine (NHC), previously demonstrated broad in
vitro antiviral activity against multiple RNA viruses and has shown a high barrier to the …

The route to an effective antiviral treatment against SARS-CoV-2 has been marked by
dozens of negative clinical trials, with thousands of patients across the globe enrolled in …

Numerous treatments exist for COVID-19, the illness caused by SARS-CoV-2 virus, although
most are not well established; among these are several small molecule antiviral agents …

Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more
than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In …

Background Using a retrospective cohort study design, we aimed to evaluate the
effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …

Coronaviruses (CoVs) are a group of RNA viruses that are associated with different
diseases in animals, birds, and humans. Human CoVs (HCoVs) have long been known to …

Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Abstract Background The SARS-CoV-2 pandemic has prompted clinicians to develop an
early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies …